-Reuters
Ikena Oncology To Present Initial Phase 1a/b Results From Novel AHR Inhibition Program At The 2022 Society For Immunotherapy Of Cancer 37th Annual Meeting
Ikena Oncology, Inc. (NASDAQ:IKNA, ", Ikena", )))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl